Previous 10 | Next 10 |
NEWARK, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the ...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +61.60% Cumulative Gain by Friday of the Week: -3.60% This week 3 out of 4 breakout stocks for members reached double digits during a short trading week. Selling of the breakout stocks prior to the end of t...
NEWARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
NEWARK, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a fireside c...
Bioblast Pharma (NASDAQ: ORPN ) +36% on announcing sale of Trehalose clinical development programs to Seelos Therapeutics. More news on: Bio Blast Pharma, Sky Solar Holdings, Intercept Pharmaceuticals, Stocks on the move, Read more ...
Total of 181 subjects enrolled with elevated liver fat and biopsy-confirmed NASH Over 80 % of subjects had baseline F2 or F3 stage fibrosis Subjects were randomized to seladelpar 10 mg, 20 mg or 50 mg or placebo Twelve-week topline liver fat data, using MRI-PDFF, expected 2...
The positive Phase 3 data -stoked rally in Intercept Pharmaceuticals is rippling out to certain other NASH players. More news on: CymaBay Therapeutics, Viking Therapeutics, Madrigal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Breakout Stock Portfolio 2019 results YTD Cumulative Weekly Max Gain YTD: +48.08% Cumulative Gain by Friday of the Week: -9.98% This week 3 out of 4 stocks reached their highs at the end of the week. Until this past Week 7, the selling of the breakout stocks prior to the end of the fix...
SAExploration Holdings (NASDAQ: SAEX ) +20% . More news on: SAExploration Holdings, Inc., Talend SA, Cerecor, Stocks on the move, Read more ...
The FDA has granted Breakthrough Therapy Designation for CymaBay Therapeutics' (NASDAQ: CBAY ) seladelpar for the treatment of early stage primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adult patients with an inadequate response to UDCA, or as monotherapy in...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...